Ingenuity Licenses Pathways Analysis Software to Avalon
News Jan 11, 2006
Ingenuity Systems and Avalon Pharmaceuticals Inc. have announced that they have entered into an agreement whereby Avalon will license Ingenuity Pathways Analysis 3.0, enhancing Avalon's drug and target discovery process.
Avalon has a focused program to harness the power of gene disruption signatures for the isolation of drugs against previously "intractable" targets.
The Ingenuity Pathways Analysis 3.0 application is being applied to the AvalonRx® platform in several selected therapeutic areas to identify biomarkers, targets, and compounds.
Ingenuity Pathways Analysis 3.0 is designed to enable researchers to model, analyze and understand the complex biological systems at the core of life science research.
Ingenuity claims that, with Ingenuity Pathways Analysis, scientists can integrate their own biological discoveries into Ingenuity networks, providing effective computation and functional analysis.
Scientists used a gene editing method called CRISPR/Cas9 to generate mice that faithfully mimic a fatal respiratory disorder in newborn infants that turns their lips and skin blue. The new laboratory model allowed researchers to pinpoint the ailment's cause and develop a potential and desperately needed nanoparticle-based treatment.READ MORE